Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 10, 2015, Pages

  Liu, Jia ^a   Wang, Lu Ning ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ANEMIA; CARDIOVASCULAR RESPONSE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HEART FAILURE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DYSFUNCTION; MYALGIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SORE THROAT; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; AGONISTS; CARDIOVASCULAR DISEASES; ISCHEMIC ATTACK, TRANSIENT; META ANALYSIS; MORTALITY; MYOCARDIAL INFARCTION; PROCEDURES; SECONDARY PREVENTION; STROKE;

CARDIOVASCULAR DISEASES; HUMANS; HYPOGLYCEMIC AGENTS; ISCHEMIC ATTACK, TRANSIENT; MYOCARDIAL INFARCTION; PPAR GAMMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION; STROKE; THIAZOLIDINEDIONES;

EID: 84973858213     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD010693.pub3     Document Type: Review

References (53)

1. Tanaka R, Okuma Y, Miyamoto N, Tanaka Y, Yamashiro K, Watada H, et al. Effects of pioglitazone in patients with impaired glucose tolerance after stroke; progress report from J-SPIRIT study. International Journal of Stroke 2010;5:195 (Abst.PO10427).
2. Tanaka R, Yamashiro K, Tanaka Y, Miyamoto N, Ueno Y, Watanabe M, et al. Effects of pioglitazone in patients with abnormal glucose metabolism after stroke. The J-SPIRIT study. Stroke 2013;44:Abst.ATP416.
3. Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Shulman GI, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003;34:1431-6.
4. Marfella R, D'Amico M, Di Filippo C, Baldi A, Siniscalchi M, Sasso FC, et al. Increased activity of the ubiquitin-proteasome system in patients with symptomatic carotid disease is associated with enhanced inflammation and may destabilize the atherosclerotic plaque: effects of rosiglitazone treatment. Journal of the American College of Cardiology 2006;47:2444-55.
5. Anonymous. PROactive study shows reduced heart attacks and strokes in type 2 diabetics on pioglitazone HCI (Actos) therapy. Cardiovascular Journal of South Africa 2005;16:286-7.
6. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A, on behalf of the PROactive Study Group. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive). Diabetes Care 2004;27:1647-53.
7. Dormandy JA, Betteridge DJ, Schernthaner G, Pirags V, Norgren L, on behalf of the PROactive investigators. Impact of peripheral arterial disease in patients with diabetes -results from PROactive (PROactive 11). Atherosclerosis 2009;202:272-81.
8. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
9. Erdmann E, Dormandy J, Wilcox R, Massi-Benedetti M, Charbonnel B. PROactive 07: Pioglitazone in the treatment of type 2 diabetes: Results of the PROactive study. Vascular Health and Risk Management 2007;3:355-70.
10. Erdmann E, Spanheimer R, Charbonnel B. Pioglitazone and the risk of cardiovascular events in patients with type 2 diabetes receiving concomitant treatment with nitrates, renin-angiotensin system blockers, or insulin: results from the PROactive study (PROactive 20). Journal of Diabetes 2010;2:212-20.
11. Wilcox R, Bousser MG, Betteridge J, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke. Results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73.
12. Wilcox R, Kupfer S, Erdmann E. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). American Heart Journal 2008;155:712-7.
13. Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, et al. Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. Diabetes, Obesity & Metabolism 2009;11:315-22.
14. Dehnavi RA. A 52 week double blind randomized controlled trial comparing the effect of rosiglitazone versus placebo on the prevention of progression of atherosclerosis in high risk patients without diabetes. Nederlands Trial Register (http://www.trialregister.nl) 2005.
15. Forst T, Wilhelm B, Pfützner A, Fuchs W, Lehmann U, Schaper F, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diabetes and Vascular Disease Research 2008;5:298-303.
16. Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. Journal of Internal Medicine 2007;261:293-305.
17. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2001;86:3452-6.
18. Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Rydén L, Neal B, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 2014;311:1515-25.
19. Meisner F, Walcher D, Gizard F, Kapfer X, Huber R, Noak A, et al. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arteriosclerosis Thrombosis and Vascular Biology 2006;26:845-50.
20. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients with diabetes mellitus. Arteriosclerosis Thrombosis and Vascular Biology 2004;24:930-4.
21. Hodis HN, Mack WJ, Zheng L, Li Y, Torres M, Sevilla D, et al. Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. Diabetes Care 2006;29:1545-53.
22. Karim R, Buchanan TA, Hodis HN, Li Y, Mack WJ. The association of smoking and subclinical atherosclerosis in type 2 diabetes: modification by duration of diabetes. Diabetic Medicine 2005;22:81-7.
23. Zheng L, Buchanan TA, Hodis HN, Li Y, Torres M, Mack WJ. Time from diagnosis of type 2 diabetes to initiation of insulin therapy is related to carotid artery intima-media thickness. Atherosclerosis 2003;170:293-9.
24. Zheng L, Hodis HN, Buchanan TA, Li Y, Mack WJ. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. American Journal of Cardiology 2007;99:956-60.
25. GlaxoSmithKline. Thiazolidinedione intervention with vitamin D evaluation (TIDE). ClinicalTrials.gov 2009.
26. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Controlled Clinical Trials 1998;19:217-31.
27. Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis 2008;199:207-14.
28. Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, et al. Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2005;90:1986-91.
29. Varghese A, Yee MS, Chan CF, Crowe LA, Keenan NG, Johnston DG, et al. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance 2009;11:24.
30. Insulin Resistance Intervention After Stroke Trial (IRIS). http://clinicaltrials.gov/ct2/show/NCT00091949.
31. Collino M, Aragno M, Castiglia S, Miglio G, Tomasinelli C, Boccuzzi G, et al. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. British Journal of Pharmacology 2010;160:1892-902.
32. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD004296.pub2]
33. Dasu MR, Park S, Devaraj S, Jialal I. Pioglitazone inhibits toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009;150:3457-64.
34. De Schryver ELLM, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001820.pub3]
35. De Schryver EL, Algra A, Kappelle LJ, van Gijn J, Koudstaal PJ. Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD001342.pub3]
36. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
37. Els T, Klisch J, Orszagh M, Hetzel A, Schulte-Mönting J, Schumacher M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. Cerebrovascular Diseases 2002;13:89-94.
38. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-22.
39. Fogg C, Kasliwal R, Shakir SA. Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study. Drug Safety 2009;32:229-37.
40. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006;37:1583-633.
41. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-8.
42. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. Jørgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study. Neurology 1997;48:891-5.
44. Melikian N, Seddon MD, Casadei B, Chowienczyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. Trends in Cardiovascular Medicine 2009;19:256-62.
45. Mooradian AD, Chehade J, Thurman JE. The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treatments in Endocrinology 2002;1:13-20.
46. Nakamura T, Yamamoto E, Kataoka K, Yamashita T, Tokutomi Y, Dong YF, et al. Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke 2007;38:3016-22.
47. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
48. Sandercock PA, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD000248.pub2]
49. Simon RP, Greenberg DA, Aminoff MJ. Stroke. Clinical Neurology. 7th Edition. New York: McGraw-Hill, 2009:292-327.
50. Sudlow CL, Mason G, Maurice JB, Wedderburn CJ, Hankey GJ. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD001246.pub2]
51. World Health Organization. The atlas of heart disease and stroke. http://www.who.int/cardiovascular_diseases/resources/atlas/en (accessed 12 May 2013).
52. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD010693]
53. Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in patients with stroke or transient ischaemic attack. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010693.pub2]